The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2021 | The challenge of survivorship in AML
Thomas W. LeBlanc, MD, MA, Duke Cancer Institute, Durham, NC, discusses survivorship in patients with acute myeloid leukemia (AML), a challenging issue due to the substantial heterogeneity seen in the disease course and treatment pathways. A major factor is how to support patients going through difficult treatment. Dr LeBlanc explains that integrative specialist palliative care helps patients cope with the adverse effects that are associated with high-dose chemotherapy as well as psychological issues they may face. Dr LeBlanc emphasizes that as more patients are receiving long-term lower-intensity treatments, research is needed to assess how AML specialists can better support patients as they go through this process of chronic survivorship. This interview was conducted at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
Disclosures
Thomas W. LeBlanc, MD, MA has received personal fees for consulting or advisory boards from AbbVie, Agios, Astellas, AstraZeneca, Amgen, CareVive, BMS/Celgene, Daiichi-Sankyo, Heron, Otsuka, Pfizer, and Seattle Genetics; royalties from UpToDate; speakers bureau fees from Agios, AbbVie, and BMS/Celgene; grants and/or research contracts from the American Cancer Society, AstraZeneca, BMS, Jazz Pharmaceuticals, the NINR / NIH, and Seattle Genetics.
